2-甲基-4-(3-硝基苯基)-噻唑 | 39541-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基-4-(3-硝基苯基)-噻唑
• 中文别名: 2-甲基-4-(3-硝基苯基)-1,3-噻唑
• 英文名称: 2-methyl-4-(3-nitrophenyl)-thiazole
• 英文别名: 2-methyl-4-(3-nitrophenyl)thiazole；2-methyl-(4'-nitrophenyl)thiazole；2-methyl-4-(3-nitro-phenyl)-thiazole；2-methyl-4-(3-nitrophenyl)-1,3-thiazole；2-Methyl-4-(m-nitrophenyl)thiazol
• CAS: 39541-91-8
• 化学式: C₁₀H₈N₂O₂S
• mdl: MFCD00838954
• 分子量: 220.252
• InChiKey: VWKXLZKNKFOCCW-UHFFFAOYSA-N

物化性质

• 沸点：
  375.9±25.0 °C(Predicted)
• 密度：
  1.330±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  87
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-甲基-4-(3-硝基苯基)-噻唑 在 盐酸 、 tin(ll) chloride 作用下， 以 乙醇 、 异丙醇 为溶剂， 反应 2.33h， 生成 (2-chloromethyl-6,7-diethoxy-quinazolin-4-yl)-[3-(2-methyl-thiazol-4-yl)-phenyl]-amine
  参考文献：
  名称：

  Anilinoquinazoline Inhibitors of Fructose 1,6-Bisphosphatase Bind at a Novel Allosteric Site:  Synthesis, In Vitro Characterization, and X-ray Crystallography

  摘要：

  The synthesis and in vitro structure-activity relationships (SAR) of a novel series of anilinoquinazolines as allosteric inhibitors of fructose-1,6-bisphosphatase (F16Bpase) are reported. The compounds have a different SAR as inhibitors of F16Bpase than anilinoquinazolines previously reported. Selective inhibition of F16Bpase can be attained through the addition of appropriate polar functional groups at the quinazoline 2-position, thus separating the F16Bpase inhibitory activity from the epidermal growth factor receptor tyrosine kinase inhibitory activity previously observed with similar structures. The compounds have been found to bind at a symmetry-repeated novel allosteric site at the subunit interface of the enzyme. Inhibition is brought about by binding to a loop comprised of residues 52-72, preventing the necessary participation of these residues in the assembly of the catalytic site. Mutagenesis studies have identified the key amino acid residues in the loop that are required for inhibitor recognition and binding.

  DOI：

  10.1021/jm010496a
• 作为产物：
  描述：

  间硝基苯乙酮 在 phenyltrimethylammonium tribromide 作用下， 反应 6.0h， 生成 2-甲基-4-(3-硝基苯基)-噻唑
  参考文献：
  名称：

  在离子液体中使用苯基三甲基三溴化铵的新型高效一锅合成2,4-二取代的噻唑和恶唑

  摘要：

  已经描述了一种新颖有效的单罐方法，该方法使用苯基三甲基三溴化铵作为原位溴化剂，然后分别与硫代酰胺/硫脲和酰胺/脲在[bmim]中反应，从取代的酮合成2,4-二取代的噻唑和恶唑。BF 4 ]离子液体。该方法的优点包括避免处理漆料化合物，有害和有毒的有机溶剂，以及产品的良率或优良率。

  DOI：

  10.1002/jhet.904

文献信息

• [EN] BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BIARYLAMIDE DE PRODUCTION DE LEUKOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012082817A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中A、B、C、R1a、R1b、R2、R3、R4a和R4b如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• [EN] IMIDAZOPYRIDAZINE KINASE INHIBITORS USEFUL TO TREATING A DISEASE OR DISORDER MEDIATED BY AAK1, SUCH AS ALZHEIMER'S DISEASE, BIPOLAR DISORDER, PAIN, SCHIZOPHRENIA<br/>[FR] INHIBITEURS D'IMIDAZOPYRIDAZINE KINASE UTILES POUR LE TRAITEMENT D'UNE MALADIE OU D'UN TROUBLE INDUIT PAR AAK1, TELS QUE LA MALADIE D'ALZHEIMER, UN TROUBLE BIPOLAIRE, LA DOULEUR, LA SCHIZOPHRÉNIE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015026574A1

  公开（公告）日：2015-02-26

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这种化合物的组合物，以及抑制AAK1的方法。
• Fructose 1,6-bisphosphatase inhibitors
  申请人：——

  公开号：US20030144308A1

  公开（公告）日：2003-07-31

  The present invention relates to certain quinazoline compounds which have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer. The invention also relates to pharmaceutical compositions and kits comprising such quinazoline compounds and to methods of using such compounds in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer.

  本发明涉及某些喹唑啉化合物，其在糖尿病、高胆固醇血症、高脂血症、糖尿病并发症和癌症治疗中具有用途。该发明还涉及含有这种喹唑啉化合物的药物组合物和配套工具，以及使用这些化合物治疗糖尿病、高胆固醇血症、高脂血症、糖尿病并发症和癌症的方法。
• Benzimidazole compounds and their use as modulators of the GABA a
  申请人：Neurosearch A/S

  公开号：US05922724A1

  公开（公告）日：1999-07-13

  The present patent application discloses compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof or an oxide thereof wherein R.sup.3 is ##STR2## wherein A, B and D each is CH, or one or two of A, B and D is N and the others are CH; R.sup.11 is phenyl, benzimidazolyl, or monocyclic heteroaryl all of which may be substituted one or more times with substituents selected from alkyl, alkoxy, phenyl, halogen, CF.sub.3, amino, nitro, cyano, acyl, acylamino, phenyl and monocyclic heteroaryl; and one of R.sup.6 and R.sup.7 is hydrogen and the other is furanyl or isoxazolyl each of which may be substituted one or more times with substituents selected from halogen, alkyl, alkoxy and phenyl. The compounds are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

  本专利申请揭示了具有以下式子##STR1##或其药学上可接受的盐或氧化物的化合物，其中R.sup.3为##STR2##其中A、B和D各为CH，或者A、B和D中的一或两个为N，其他为CH；R.sup.11为苯基、苯并咪唑基或单环杂环芳基，均可被取代一次或多次，所述取代基选择自烷基、烷氧基、苯基、卤素、CF.sub.3、氨基、硝基、氰基、酰基、酰胺基、苯基和单环杂环芳基；R.sup.6和R.sup.7中的一个为氢，另一个为呋喃基或异噁唑基，均可被取代一次或多次，所述取代基选择自卤素、烷基、烷氧基和苯基。这些化合物可用于治疗各种中枢神经系统疾病，如癫痫和其他惊厥性疾病、焦虑、睡眠障碍和记忆障碍。
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Yang Bingwei Vera

  公开号：US20100063051A1

  公开（公告）日：2010-03-11

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I) an enantiomer, diastereomer, tautomer, solvate (e.g. a hydrate), or a pharmaceutically-acceptable salt, thereof, wherein: M is selected from alkyl, substituted alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl, provided that if M is alkyl then R 6 and R 7 taken together with the carbon atom to which they are both attached are selected from a group other than cycloalkyl; Q is selected from (i) hydrogen, C 1 -C 4 alkyl, and substituted C 1 -C 4 alkyl; or (ii) Q and R 6 are combined with the carbon atoms to which they are attached to form a 3- to 6-membered cycloalkyl; or (iii) Q and M a M are combined with the carbon atom(s) to which they are attached to form a 3- to 7-membered ring containing 1-2 heteroatoms which are independently selected from the group consisting of O, S, SO 2 , and N which ring may be optionally substituted with 0-2 R 5 groups or carbonyl; Z is selected from cycloalkyl, heterocyclo, aryl, or heteroaryl; and M a , Z a , R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 22 are as defined herein. Also provided are pharmaceutical compositions and methods of treating metabolic and inflammatory- or immune-associated diseases or disorders using said compounds.

  提供了一些新型非类固醇化合物，其在治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病中非常有用，包括炎症和免疫性疾病、肥胖症和糖尿病，具有以下结构公式（I）的对映体、顺反异构体、互变异构体、溶剂化物（例如水合物）或其医药上可接受的盐，其中：M选自烷基、取代烷基、环烷基、芳基、杂环烷基和杂芳基，但如果M是烷基，则R6和R7与它们都连接的碳原子一起选自环烷基之外的一组；Q选自（i）氢、C1-C4烷基和取代的C1-C4烷基；或（ii）Q和R6与它们连接的碳原子结合形成3-到6-成员的环烷基；或（iii）Q和MaM与它们连接的碳原子结合形成1-2个杂原子（独立于O、S、SO2和N组成）的3-到7-成员的环，该环可以选择性地用0-2个R5基团或羰基取代；Z选自环烷基、杂环烷基、芳基或杂芳基；而Ma、Za、R1、R2、R3、R4、R6、R7和R22如本文所定义。还提供了制药组合物和使用所述化合物治疗代谢和炎症或免疫相关疾病或紊乱的方法。